CMAB009

anti-epidermal growth factor receptor monoclonal antibody for treatment of solid tumors

Networked: 3 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        CMAB009: 3
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        CMAB009: 3
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        CMAB009: 3

Experts

1.	He, Xiaohui: 2 articles (01/2019 - 01/2011)
2.	Shi, Yuankai: 2 articles (01/2019 - 01/2011)
3.	Sun, Yan: 2 articles (01/2019 - 09/2011)
4.	Bai, Li: 1 article (01/2019)
5.	Bi, Feng: 1 article (01/2019)
6.	Chen, Yigui: 1 article (01/2019)
7.	Cheng, Ying: 1 article (01/2019)
8.	Hu, Xiaohua: 1 article (01/2019)
9.	Li, Jin: 1 article (01/2019)
10.	Li, Yuhong: 1 article (01/2019)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2011 - "The study results suggest that CMAB009 shows acceptable tolerance and primary efficacy and should be studied as a treatment in patients with advanced chemotherapy-resistant epithelial malignancies." 01/01/2011 - "The purpose of this study was to evaluate the safety, pharmacokinetics, and potential benefit of CMAB009 in Chinese patients with advanced chemotherapy-resistant epithelial malignancies. " 09/06/2011 - "[Phase I study of anti-EGFR monoclonal antibody (CMAB009) in patients with advanced cancer]." 09/06/2011 - "To characterize the safety profiles and serum pharmacokinetic effects of anti-epidermal growth factor receptor monoclonal antibody (CMAB009) in advanced cancer patients and evaluate the preliminary evidence of its anti-tumor activity. "
2.	Colorectal Neoplasms (Colorectal Cancer) 01/01/2019 - "CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial."
3.	Disease Progression 01/01/2019 - "Patients receiving irinotecan-only were permitted to switch to CMAB009 therapy on disease progression and were grouped as the sequential-CMAB009 arm. "
4.	Paronychia 01/01/2019 - "However, patients treated with CMAB009 had an increased risk of skin rash (66.9% vs. 5.5%, P < 0.001) and paronychia (9.8% vs. 0.0%, P < 0.001). "
5.	Hypersensitivity (Allergy) 01/01/2019 - "Anti-drug antibodies (ADA) were detected in 3.6% of patients, and only 0.9% of patients who received CMAB009 experienced hypersensitivity reactions. "

Related Drugs and Biologics

1.	Monoclonal Antibodies
2.	Oxaliplatin (Eloxatin)
3.	Irinotecan (Camptosar)
4.	ErbB Receptors (EGF Receptor)
5.	Antibodies

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics